Latest Compliance News

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

Arafura Rare Earths has locked in binding cornerstone equity agreements worth approximately A$230 million, bolstering its path to a final investment decision for the Nolans Project. The company also acquired critical camp infrastructure and is progressing technology development and offtake negotiations amid supportive government frameworks.

Westgold Resources maintained FY26 gold production guidance with 93,145oz in Q3, backed by a record A$7,080/oz gold price and a robust A$285M underlying cash build. The company approved a $145M expansion of its Higginsville processing hub to boost capacity and cut costs.

Asian Battery Metals has completed its acquisition of the Maikhan Uul Cu-Au VMS Project and is poised to start a fully permitted 2026 drilling campaign across its Mongolian copper and battery metals assets, backed by $5.25 million in cash.

Sprintex has locked in an exclusive Saudi Arabia distribution agreement with Washnah Trading and landed a tender for the King Salman International Airport wastewater project, opening a potential $5 million supply opportunity.

Tyranna Resources has identified new gold anomalies at its Chinguar Gold Project and progressed licence security and bulk sampling plans at its Namibe Lithium and Caesium Project in Angola.

Arrow Minerals secures $2.25 million to fund the acquisition of an 80% stake in the Yarraloola Copper Project and plans a 2,000m drilling campaign targeting copper and gold in WA’s Pilbara.

Elsight’s Halo connectivity platform has gained critical approval on the U.S. Department of War’s DCMA Blue List, enabling rapid military procurement amid a historic US$75 billion drone budget surge.

FortifAI’s Nol8 FPGA appliance dramatically reduces AI infrastructure costs by replacing up to 60,000 CPUs, slashing annual operational expenses from millions to tens of thousands of dollars.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.